Amgen also tested MariTide in a population with Type 2 diabetes, a group that tends to lose less weight with the new obesity ...

Amgen stock crashed Tuesday after its weight-loss drug met Wall Street's expectations, but was only on par with Eli Lilly's ...

Amgen stock crashed Tuesday after its weight-loss drug met Wall Street's expectations, but was only on par with Eli Lilly's ...

Analysts were expecting the treatment to achieve an average weight loss of about 20% to 25% after one year of treatment, ...

CNBC’s Jim Cramer explains why he is keeping an eye on shares of Amgen.

Amgen Inc. shares fell after its experimental obesity shot helped patients lose up to 20% of their body weight in a yearlong ...

The results shed light on how MariTide may measure up to weight loss injections from Novo Nordisk and Eli Lilly and other ...

Amgen's experimental drug MariTide led to an average weight loss of up to 20% in a year-long mid-stage trial of nearly 600 ...

Amgen Inc.’s stock AMGN tumbled 7.8% in early trade Tuesday, after the company said a mid-stage trial of its weight-loss ...

Amgen's latest once-monthly weight loss drug data looks "OK," analysts say, as its path to approval still remains murky.

MariTide, which like Eli Lilly’s Zepound is a dual agonist of the GLP-1 and GIP receptors, demonstrated an average weight ...

Amgen’s MariTide results are at the lower end of investors’ expectation of 20% to 25% weight loss. The much-anticipated ...